Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus PEDIATRIC LTA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus PEDIATRIC LTA KIT.
LIDOCAINE HYDROCHLORIDE VISCOUS vs PEDIATRIC LTA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials. It also has antiarrhythmic properties (Class Ib) by accelerating repolarization and reducing automaticity in cardiac tissues.
PEDIATRIC LTA KIT contains lidocaine, tetracaine, and epinephrine. Lidocaine and tetracaine are amide and ester local anesthetics, respectively, that block voltage-gated sodium channels, preventing nerve impulse propagation. Epinephrine is a sympathomimetic that causes vasoconstriction, prolonging local anesthetic effect and reducing systemic absorption.
Adult: 15 mL (300 mg) orally every 3 hours, not to exceed 8 doses in 24 hours. Viscous formulation swished and swallowed.
Not applicable. Pediatric LTA Kit is a topical lidocaine/tetracaine patch for dermal anesthesia. Adult dose: apply one patch to intact skin for 20-30 minutes prior to procedure; remove prior to procedure. Maximum 3 patches per session. Not for systemic use.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours (adults); prolonged in heart failure (2.5–4 hours) or hepatic disease (up to 5–7 hours). Context: short t1/2 limits toxic accumulation with topical use.
2-3 hours (terminal) in children with normal renal function; prolonged in renal impairment
Renal: ~90% as metabolites (mainly 4-hydroxy-2,6-xylidine and glucuronides), <10% unchanged. Biliary/fecal: minor (<5%).
Renal (95% as unchanged drug), fecal (5%)
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic